Pfizer (PFE) is facing the expiration of patents on several of its major blockbuster drugs. This is a normal situation for pharmaceutical companies, but Pfizer currently does not appear to have enough new drugs to replace those losing patent protection. The biggest impact is expected to come from the heart disease medications Eliquis and Vyndaqel, whose patent protections are set to expire in 2028.
These impending patent expirations are the primary reason for the general pessimism Wall Street currently holds toward Pfizer’s stock. However, for long-term dividend investors, this could present an opportunity—as long as they do not mind taking on slightly higher risk in exchange for higher returns.
A major challenge for pharmaceutical companies is that patent expirations follow a fixed schedule, while drug development cannot be advanced according to a set plan. Consequently, there can be a mismatch between the revenue loss caused by patent expirations and the revenue generated by new drugs. At least until 2028, Pfizer is likely to face revenue pressure, after which its business is expected to return to growth.
More concerning is that, as of the end of the first quarter of 2026, Pfizer’s payout ratio had far exceeded 100%, reaching 130%. Investors have good reason to feel uneasy about Pfizer’s high 6.6% dividend yield. However, dividends are paid using cash flow, not profits. Therefore, Pfizer can use debt or cash on its balance sheet to support its dividends until profitability improves. It is worth noting that the cash dividend payout ratio (i.e., dividends relative to cash flow) is currently hovering around 100%. Since the financial impact of dividends is reflected on the cash flow statement, this metric may better represent the company’s true ability to pay dividends. Although 100% is still high, Pfizer clearly has the capacity to continue maintaining its current dividend level.
From a broader perspective, a 6.6% dividend yield is significant. The current dividend yield of the S&P 500 Index (^GSPC) is only 1.1%, the average dividend yield for the pharmaceutical industry is 1.7%, and the average for the entire healthcare sector is also 1.7%. Pfizer’s dividend yield is six times that of the S&P 500 and more than three times that of other healthcare companies (including pharmaceutical firms). In comparison, the additional risk does not seem as large as the gap in dividend yields.
Nevertheless, the ultimate dividend decision lies with Pfizer’s board of directors. If the board wishes to continue paying dividends, and the company has the financial capacity to support them (which currently appears to be the case), then dividends will continue to be distributed. Management has clearly stated this position, specifically noting that the company’s goal is to maintain the dividend. If the board were inclined to cut the dividend, the CEO would be unlikely to make such remarks.
In the long term, Pfizer is one of the world’s most dominant healthcare companies, with over a century of successful history. The current challenges—fairly common in the pharmaceutical industry—are almost certainly not capable of permanently crippling Pfizer.
In summary, while Pfizer’s dividend yield is far above market and industry averages, and the company has the ability to support its dividends through cash flow and its balance sheet, the 130% payout ratio and impending patent expiration pressures still pose risks that cannot be ignored. For long-term dividend investors with a higher risk tolerance, Pfizer’s stock may offer an attractive risk-reward ratio. In the worst-case scenario, the dividend could be cut, but historical experience suggests that it is unlikely to be eliminated entirely and could resume growth relatively quickly. If the dividend is maintained, investors will not only receive high dividend payouts but also have the opportunity to benefit from share price appreciation. Overall, the downside risk for long-term investors is relatively limited, while the potential rewards are quite considerable.
